Lack of clinically significant drug–drug interactions between the third‐generation integrase strand transfer inhibitor VH4524184 (VH‐184) and combined oral contraceptives

Documenti analoghi

• A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
  di: Jane Knöchel, et al.
  Pubblicazione: (2024)
• Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
  di: C. Hu, et al.
  Pubblicazione: (2025)
• Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption
  di: Sarah Alrubia, et al.
  Pubblicazione: (2025)
• The use of different types of networks, alone and in combination, for drug target identification
  di: Paolo Parini
  Pubblicazione: (2025)
• Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
  di: C. Hu, et al.
  Pubblicazione: (2025)